VEGFA and renal cell carcinoma: In the past two decades, improved understanding of RCC cancer biology has led to approval of vascular endothelial growth factor (VEGF) pathway drugs including tyrosine kinase inhibitors (TKI) and the mammalian target of rapamycin (mTOR) inhibitors and more recently immune checkpoint inhibitors (ICI) and combination of these agents.